卡培他滨联合拉帕替尼治疗HER2阳性乳腺癌的效果观察  

Effects of capecitabine combined with lapatinib on HER2-positive breast cancer

作　　者：卜德永[1] 赵连[1] 周应强[1] Bu Deyong;Zhao Lian;Zhou Yingqiang(Department of General Medicine,the Fifth People’s Hospital of Datong,Datong 037009,China)

机构地区：[1]山西省大同市第五人民医院普通外科,037009

出　　处：《中国实用医刊》2020年第17期95-98,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨卡培他滨联合拉帕替尼治疗人表皮生长因子受体-2(HER2)阳性乳腺癌的效果及对患者胸苷激酶(TK1)、胰岛素样子生长因子-1(IGF-1)水平的影响。方法回顾性分析2018年1月至2019年12月于大同市第五人民医院接受治疗的85例HER2阳性乳腺癌患者的临床资料,根据其临床治疗方案分为对照组(42例,卡培他滨)与观察组(43例,卡培他滨+拉帕替尼)。治疗6个月后评估两组临床疗效,并比较两组治疗前及治疗6个月后TK1、IGF-1水平,同时记录两组治疗期间不良反应发生情况。结果观察组临床总有效率(86.05%,37/43)高于对照组(66.67%,28/42),P<0.05。治疗6个月后,两组TK1、IGF-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组恶心及呕吐、心脏损伤、肝功能异常、皮疹、间质性肺炎等不良反应发生率比较差异未见统计学意义(P>0.05)。结论卡培他滨与拉帕替尼联合治疗HER2阳性乳腺癌患者可提高临床疗效,降低特异性肿瘤标志物水平,且不会增加不良反应发生率。Objective To investigate the effects of capecitabine combined with lapatinib on the levels of thymidine kinase(TK1)and insulin-like growth factor 1(IGF-1)in patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods The clinical data from 85 patients with HER2-positive breast cancer who were treated in the Fifth People’s Hospital of Datong from January 2018 to December 2019 were retrospectively analyzed.They were divided into the control group(42 cases,treated with capecitabine)and the observation group(43 cases,treated with capecitabine and lapatinib)according to treatment plans.After 6 months of treatment,the clinical efficacy of the two groups was evaluated,and the levels of TK1 and IGF-1 were compared between the two groups before treatment and after 6 months of treatment.And the incidence of adverse reactions of the two groups during the treatment were recorded.Results The total effective rate of the observation group was 86.05%(37/43),higher than the 66.67%(28/42)of the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,the levels of TK1 and IGF-1 of the two groups were lower than preoperative levels,and the observation group had lower levels than the control group,and the difference was statistically significant(P<0.05).There was no significant difference in incidences of nausea,vomiting,heart injury,abnormal liver function,skin rash and interstitial pneumonia between the two groups(P>0.05).Conclusions The combination of capecitabine and lapatinib in the treatment of HER2-positive breast cancer patients can improve clinical efficacy,reduce the level of specific tumor markers,and will not increase incidence of adverse reactions.

关 键 词：乳腺癌 人表皮生长因子受体-2阳性 拉帕替尼 卡培他滨 胸苷激酶 胰岛素样生长因子-1 

分 类 号：R737.9[医药卫生—肿瘤]